Drug intelligence / Profile preview

Versatile Antimicrobial

Development stage: Preclinical
Lead developer: Kawin Technology
Modality: Small Molecules
Administration: Oral

Overview

Versatile Antimicrobial (also identified by the code name KW-045) is an investigational oral small molecule drug developed by Kawin Technology. It is characterized as a broad-spectrum antimicrobial and antiviral agent, currently being evaluated for the adjuvant treatment of Nasopharyngeal Carcinoma (NPC). Given the strong association between NPC and the Epstein-Barr Virus (EBV), this agent is designed to target viral factors that contribute to tumor progression or recurrence. The drug is formulated as a tablet and is intended to supplement standard-of-care therapies in the adjuvant setting to improve clinical outcomes for patients with NPC.

Other names: Versatile Antimicrobial (new)Broad-spectrum Antiviral Drug

Beyond the preview

Go deeper on Versatile Antimicrobial.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Versatile Antimicrobial.

Explore the full profile